170 related articles for article (PubMed ID: 21544807)
1. Aberrations of a cell adhesion molecule CADM4 in renal clear cell carcinoma.
Nagata M; Sakurai-Yageta M; Yamada D; Goto A; Ito A; Fukuhara H; Kume H; Morikawa T; Fukayama M; Homma Y; Murakami Y
Int J Cancer; 2012 Mar; 130(6):1329-37. PubMed ID: 21544807
[TBL] [Abstract][Full Text] [Related]
2. Promoter hypermethylation of the potential tumor suppressor DAL-1/4.1B gene in renal clear cell carcinoma.
Yamada D; Kikuchi S; Williams YN; Sakurai-Yageta M; Masuda M; Maruyama T; Tomita K; Gutmann DH; Kakizoe T; Kitamura T; Kanai Y; Murakami Y
Int J Cancer; 2006 Feb; 118(4):916-23. PubMed ID: 16152585
[TBL] [Abstract][Full Text] [Related]
3. Differential Contribution of Cadm1-Cadm3 Cell Adhesion Molecules to Peripheral Myelinated Axons.
Sukhanov N; Vainshtein A; Eshed-Eisenbach Y; Peles E
J Neurosci; 2021 Feb; 41(7):1393-1400. PubMed ID: 33397712
[TBL] [Abstract][Full Text] [Related]
4. Cell adhesion molecule 4 suppresses cell growth and metastasis by inhibiting the Akt signaling pathway in non-small cell lung cancer.
Luo F; Zhao Y; Liu J
Int J Biochem Cell Biol; 2020 Jun; 123():105750. PubMed ID: 32325280
[TBL] [Abstract][Full Text] [Related]
5. Downregulation of junctional adhesion molecule-A is involved in the progression of clear cell renal cell carcinoma.
Gutwein P; Schramme A; Voss B; Abdel-Bakky MS; Doberstein K; Ludwig A; Altevogt P; Hansmann ML; Moch H; Kristiansen G; Pfeilschifter J
Biochem Biophys Res Commun; 2009 Mar; 380(2):387-91. PubMed ID: 19250634
[TBL] [Abstract][Full Text] [Related]
6. Synaptic adhesion molecules in Cadm family at the neuromuscular junction.
Tanabe Y; Fujita E; Hayashi YK; Zhu X; Lubbert H; Mezaki Y; Senoo H; Momoi T
Cell Biol Int; 2013 Jul; 37(7):731-6. PubMed ID: 23505055
[TBL] [Abstract][Full Text] [Related]
7. Aberrant expression of tumor suppressors CADM1 and 4.1B in invasive lesions of primary breast cancer.
Takahashi Y; Iwai M; Kawai T; Arakawa A; Ito T; Sakurai-Yageta M; Ito A; Goto A; Saito M; Kasumi F; Murakami Y
Breast Cancer; 2012 Jul; 19(3):242-52. PubMed ID: 21526423
[TBL] [Abstract][Full Text] [Related]
8. Decreased expression of CADM1 and CADM4 are associated with advanced stage breast cancer.
Saito M; Goto A; Abe N; Saito K; Maeda D; Ohtake T; Murakami Y; Takenoshita S
Oncol Lett; 2018 Feb; 15(2):2401-2406. PubMed ID: 29434950
[TBL] [Abstract][Full Text] [Related]
9. Imprinted DLK1 is a putative tumor suppressor gene and inactivated by epimutation at the region upstream of GTL2 in human renal cell carcinoma.
Kawakami T; Chano T; Minami K; Okabe H; Okada Y; Okamoto K
Hum Mol Genet; 2006 Mar; 15(6):821-30. PubMed ID: 16439445
[TBL] [Abstract][Full Text] [Related]
10. Involvement of a cell adhesion molecule, TSLC1/IGSF4, in human oncogenesis.
Murakami Y
Cancer Sci; 2005 Sep; 96(9):543-52. PubMed ID: 16128739
[TBL] [Abstract][Full Text] [Related]
11. Preneoplastic and neoplastic lesions of rat hereditary renal cell tumors express markers of proximal and distal nephron.
Wolf DC; Whiteley HE; Everitt JI
Vet Pathol; 1995 Jul; 32(4):379-86. PubMed ID: 7483212
[TBL] [Abstract][Full Text] [Related]
12. Genetic and epigenetic control of UNC5C expression in human renal cell carcinoma.
Lv D; Zhao W; Dong D; Qian XP; Zhang Y; Tian XJ; Zhang J
Eur J Cancer; 2011 Sep; 47(13):2068-76. PubMed ID: 21600761
[TBL] [Abstract][Full Text] [Related]
13. Expression of a splicing variant of the CADM1 specific to small cell lung cancer.
Kikuchi S; Iwai M; Sakurai-Yageta M; Tsuboi Y; Ito T; Maruyama T; Tsuda H; Kanai Y; Onizuka M; Sato Y; Murakami Y
Cancer Sci; 2012 Jun; 103(6):1051-7. PubMed ID: 22429880
[TBL] [Abstract][Full Text] [Related]
14. Genetic deletion of Cadm4 results in myelin abnormalities resembling Charcot-Marie-Tooth neuropathy.
Golan N; Kartvelishvily E; Spiegel I; Salomon D; Sabanay H; Rechav K; Vainshtein A; Frechter S; Maik-Rachline G; Eshed-Eisenbach Y; Momoi T; Peles E
J Neurosci; 2013 Jul; 33(27):10950-61. PubMed ID: 23825401
[TBL] [Abstract][Full Text] [Related]
15. Tumor suppressor CADM1 is involved in epithelial cell structure.
Sakurai-Yageta M; Masuda M; Tsuboi Y; Ito A; Murakami Y
Biochem Biophys Res Commun; 2009 Dec; 390(3):977-82. PubMed ID: 19854157
[TBL] [Abstract][Full Text] [Related]
16. Tumor suppressor activity and epigenetic inactivation of hepatocyte growth factor activator inhibitor type 2/SPINT2 in papillary and clear cell renal cell carcinoma.
Morris MR; Gentle D; Abdulrahman M; Maina EN; Gupta K; Banks RE; Wiesener MS; Kishida T; Yao M; Teh B; Latif F; Maher ER
Cancer Res; 2005 Jun; 65(11):4598-606. PubMed ID: 15930277
[TBL] [Abstract][Full Text] [Related]
17. CMTM4 is frequently downregulated and functions as a tumour suppressor in clear cell renal cell carcinoma.
Li T; Cheng Y; Wang P; Wang W; Hu F; Mo X; Lv H; Xu T; Han W
J Exp Clin Cancer Res; 2015 Oct; 34():122. PubMed ID: 26474560
[TBL] [Abstract][Full Text] [Related]
18. Cell adhesion and prostate tumor-suppressor activity of TSLL2/IGSF4C, an immunoglobulin superfamily molecule homologous to TSLC1/IGSF4.
Williams YN; Masuda M; Sakurai-Yageta M; Maruyama T; Shibuya M; Murakami Y
Oncogene; 2006 Mar; 25(10):1446-53. PubMed ID: 16261159
[TBL] [Abstract][Full Text] [Related]
19. Downregulation of CLDN7 due to promoter hypermethylation is associated with human clear cell renal cell carcinoma progression and poor prognosis.
Li Y; Gong Y; Ning X; Peng D; Liu L; He S; Gong K; Zhang C; Li X; Zhou L
J Exp Clin Cancer Res; 2018 Nov; 37(1):276. PubMed ID: 30428910
[TBL] [Abstract][Full Text] [Related]
20. Nonpapillary and papillary renal cell carcinoma: a cytogenetic and phenotypic study.
Hughson MD; Johnson LD; Silva FG; Kovacs G
Mod Pathol; 1993 Jul; 6(4):449-56. PubMed ID: 8415591
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
